VYYR.F Stock Overview
Engages in the acquiring, exploring, and developing raw materials for pharmaceutical products in the province of British Columbia, Canada, and the state of Utah. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Voyageur Pharmaceuticals Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.05 |
52 Week High | CA$0.078 |
52 Week Low | CA$0.0005 |
Beta | 0.30 |
11 Month Change | -5.66% |
3 Month Change | n/a |
1 Year Change | 52.91% |
33 Year Change | -33.86% |
5 Year Change | -17.63% |
Change since IPO | -14.68% |
Recent News & Updates
Recent updates
Shareholder Returns
VYYR.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -1.9% | -0.5% |
1Y | 52.9% | 13.2% | 32.3% |
Return vs Industry: VYYR.F exceeded the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: VYYR.F exceeded the US Market which returned 32.3% over the past year.
Price Volatility
VYYR.F volatility | |
---|---|
VYYR.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VYYR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VYYR.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Brent Willis | voyageurpharmaceuticals.ca |
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products in the province of British Columbia, Canada, and the state of Utah. It develops barium, iodine-based APIs, and imaging contrast agents for medical radiology. The company was formerly known as Voyageur Minerals Ltd.
Voyageur Pharmaceuticals Ltd. Fundamentals Summary
VYYR.F fundamental statistics | |
---|---|
Market cap | US$6.95m |
Earnings (TTM) | -US$1.09m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.4x
P/E RatioIs VYYR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VYYR.F income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$1.53m |
Earnings | -CA$1.53m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.011 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 4.2% |
How did VYYR.F perform over the long term?
See historical performance and comparison